Barclays
MIRA icon

Barclays’s MIRA Pharmaceuticals MIRA Stock Holding History

Barclays’s Portfolio MIRA Stock Details MIRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150 Buy
+159
New +$161 ﹤0.01% 5146

Other funds holding MIRA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CSI
Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FAB
First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's MIRA Position: Q2 2026 in Review

Barclays opened a new position in MIRA Pharmaceuticals (MIRA) in Q2 2026: 159 shares worth $150. The stake represents ﹤0.01% of the portfolio and ranks #5146 among its holdings.

26 funds tracked by Wall St. Rank hold MIRA as of Q2 2026.

  • Barclays held 159 shares of MIRA Pharmaceuticals worth $150 as of Q2 2026.
  • MIRA Pharmaceuticals was a new Barclays position in Q2 2026.
  • MIRA Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5146 holding.
  • 26 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.